Rubicon Research
↗Thane, India
Rubicon Research is an IP-led specialty pharmaceutical company and CDMO that leverages proprietary drug delivery technologies and specialized formulation development skills. The company focuses on creating high-quality products across various dosage forms, including oral solids, liquids, sterile injectables, and drug-device combinations.
Rubicon operates a global development network with R&D centers in India and Canada, the latter of which serves as a Center of Excellence for nasal and pulmonary product development. The company is a portfolio company of the growth equity investor General Atlantic.
CLASSIFICATION
SIZE & FINANCIALS
Founded:1999
Ownership:private
Status:operating
FUNDING
Investors:General Atlantic
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Drug-device combinations
Active Trials:0
Trial Phases:-
FDA Approvals:69
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Rubicon Research Canada Limited
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Parag Sancheti - CEO
LINKS
Website:rubicon-canada.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Rubicon Research and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Rubicon Research. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.